The findings confirm that allosteric inhibition of integrase is clinically viable, validating a new antiviral drug class.

Cabotegravir was already approved for use in England and Wales as part of a combination treatment for people living with HIV.

NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it will be ...

A recently approved twice-yearly injection to prevent HIV may warrant a higher price, but thousands of dollars more?  CVS Caremark’s chief medical officer calls on Gilead Sciences to lower the $28,000 ...

Intracellular living therapeutics convert cellular signals into coordinated healing programs Get small and look inside. I ...

The Skaggs School of Pharmacy and Pharmaceutical Sciences is proud to welcome four outstanding new clinical faculty members ...

GSK raised its 2025 sales and earnings forecasts on Wednesday as its speciality HIV and cancer drugs posted double digit ...

The rate of HIV infection continues to climb globally. Around 40 million people live with HIV-1, the most common HIV strain.

CVS Caremark, the largest PBM in the U.S., tells activists Gilead needs to lower the price of its new HIV drug to get on ...

Patients with multidrug resistant HIV infection who switch to a single tablet of bictegravir/emtricitabine/tenofovir ...

Sotatercept-csrk is approved for improving exercise capacity and reducing clinical worsening in PAH patients, following FDA ...

This long-acting antiretroviral medicine offers protection for six months at a time, providing a transformative alternative for millions. The post SA first in Africa to approve ‘most effective’ HIV ...